KOLON LIFE SCIENCE Inc.
Founded in 2000 and listed on the KOSDAQ in 2009, Kolon Life Science is a raw pharmaceutical materials and bio-CDMO company that developed the cell and gene therapy Invossa-K.
As of 2026-10-10, KOLON LIFE SCIENCE Inc. has 22 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- Invossa-KCell and gene therapy for osteoarthritis
- APIs and pharmaceutical intermediatesRaw materials for new and generic synthetic drugs
- Antimicrobial agentsFunctional material inhibiting bacterial growth
- Biopharmaceutical CDMOContract development/manufacturing and technology licensing for biopharmaceuticals
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2012–2017 (Phase 3 2 · Phase 2 1)
- Phase 3인보사케이주2017-11-22
16 trial sites
- Phase 3인보사케이주2013-08-06
12 trial sites
- Phase 2인보사케이주2012-04-02
6 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedActive not recruiting · 2022-07 · NCT05613569
Phase 1/2 · Completed · 2020-04 · NCT04238793
Phase 3 · Unknown · 2018-02 · NCT03383471
Unknown · 2017-07 · NCT03412864
Phase 3 · Completed · 2013-11 · NCT02072070
Phase 2 · Completed · 2012-10 · NCT01825811
Phase 2 · Completed · 2011-07 · NCT01671072
Phase 2 · Completed · 2009-08 · NCT02341378
Phase 1 · Completed · 2007-02 · NCT02341391
R&D and key agreements
Source: DART corporate disclosure인보사케이주 · 골관절염 · The world's first cell and gene therapy for osteoarthritis, led by research institute director Dr. Kim Su-jeong.
신경병증성 통증 치료제 · 신경병증성 통증 · One of Kolon Life Science's biopharmaceutical pipeline programs.
종양살상바이러스 · 암 · One of Kolon Life Science's biopharmaceutical pipeline programs (oncolytic virus).
Key disclosures
KRX KIND via OpenDARTShow 27 more events
Publications
PubMed · affiliation-matched- KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma.
Molecular therapy. Oncology · 2026-06 · Park K, Seo J, Lee S 외 7
- KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer.
Frontiers in oncology · 2026-01 · Seo J, Park K, Lee S 외 7
- TissueGene-C induces long-term analgesic effects through regulation of pain mediators and neuronal sensitization in a rat monoiodoacetate-induced model of osteoarthritis pain.
Osteoarthritis and cartilage · 2023-12 · Park EH, Seo J, Lee Y 외 5
- Combination Gene Delivery Reduces Spinal Cord Pathology in Rats With Peripheral Neuropathic Pain.
The journal of pain · 2023-12 · Ji H, Kim KR, Park JJ 외 4
- Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus.
Molecular therapy oncolytics · 2023-09 · Hong SO, Kim J, Lee S 외 13
- The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
Therapeutic advances in musculoskeletal disease · 2022-01 · Kim H, Seo J, Lee Y 외 5
- Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Journal of experimental & clinical cancer research : CR · 2021-09 · Kang H, Lee S, Kim K 외 5
- Calbindin regulates Kv4.1 trafficking and excitability in dentate granule cells via CaMKII-dependent phosphorylation.
Experimental & molecular medicine · 2021-07 · Kim KR, Jeong HJ, Kim Y 외 7
- Generation of a Novel Oncolytic Vaccinia Virus Using the IHD-W Strain.
Human gene therapy · 2021-05 · Shin J, Hong SO, Kim M 외 11
- TissueGene-C promotes an anti-inflammatory micro-environment in a rat monoiodoacetate model of osteoarthritis via polarization of M2 macrophages leading to pain relief and structural improvement.
Inflammopharmacology · 2020-10 · Lee H, Kim H, Seo J 외 6
Show 12 more publications
- AAV-Mediated Combination Gene Therapy for Neuropathic Pain: GAD65, GDNF, and IL-10.
Molecular therapy. Methods & clinical development · 2020-09 · Kim D, Kim KR, Kwon Y 외 8
- Munc18-1 induces conformational changes of syntaxin-1 in multiple intermediates for SNARE assembly.
Scientific reports · 2020-07 · Lee S, Shin J, Jung Y 외 5
- Results of a Phase II Study to Determine the Efficacy and Safety of Genetically Engineered Allogeneic Human Chondrocytes Expressing TGF-β1.
The journal of knee surgery · 2020-02 · Lee B, Parvizi J, Bramlet D 외 6
- An MRI Evaluation of Patients Who Underwent Treatment with a Cell-Mediated Gene Therapy for Degenerative Knee Arthritis: A Phase IIa Clinical Trial.
The journal of knee surgery · 2017-09 · Cho JJ, Totterman S, Elmallah RK 외 3
- Effect of cationic monomer content on polyacrylamide copolymers by frit-inlet asymmetrical flow field-flow fractionation/multi-angle light scattering.
Journal of chromatography. A · 2017-06 · Lee H, Kim JY, Choi W 외 1
- Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
Bioorganic & medicinal chemistry letters · 2017-06 · Cheruvallath ZS, Gwaltney SL, Sabat M 외 8
- Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ.
BMC musculoskeletal disorders · 2017-05 · Lim CL, Lee YJ, Cho JH 외 4
- Characterization of ultrahigh-molecular weight cationic polyacrylamide using frit-inlet asymmetrical flow field-flow fractionation and multi-angle light scattering.
Journal of chromatography. A · 2016-01 · Woo S, Lee JY, Choi W 외 1
- A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee.
The bone & joint journal · 2015-07 · Lee MC, Ha CW, Elmallah RK 외 5
- Type II collagen and glycosaminoglycan expression induction in primary human chondrocyte by TGF-β1.
BMC musculoskeletal disorders · 2015-06 · Yoon HJ, Kim SB, Somaiya D 외 7
- Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccines.
Environmental health and toxicology · 2014-01 · Moon SH, Kim DY, Lee JM 외 11
- Identification of Streptomyces sp. KH29, which produces an antibiotic substance processing an inhibitory activity against multidrug-resistant Acinetobacter baumannii.
Journal of microbiology and biotechnology · 2010-12 · Lee KH, Kim KW, Rhee KH
Patents
KIPRIS · applicant-matchedWithdrawn · 2026-06 · Application 1020260104128
US · Published · 2026-02 · Application 19545383
Published · 2024-07 · Application 1020240088108
Registered · 2024-05 · Application 1020240069082
Registered · 2024-03 · Application 1020240030932
US · Published · 2023-02 · Application 18108849
PCT · Published · 2022-12 · Application PCT/KR2022/020710
PCT · Published · 2022-12 · Application PCT/KR2022/020699
Withdrawn · 2022-12 · Application 1020220178071
Withdrawn · 2022-12 · Application 1020220178072
Show 164 more patents
US · Published · 2022-07 · Application 17876293
CN · Published · 2022-03 · Application 202280020958.X
US · Published · 2022-03 · Application 18281412
EP · Published · 2022-03 · Application 22767554.3
PCT · Published · 2022-03 · Application PCT/KR2022/003444
Rejected · 2022-03 · Application 1020220030880
US · Published · 2021-12 · Application 17543911
CN · Published · 2021-06 · Application 202180044370.3
US · Published · 2021-06 · Application 18011789
EP · Published · 2021-06 · Application 21829516.0
PCT · Published · 2021-06 · Application PCT/KR2021/007835
Published · 2021-06 · Application 1020227045079
PCT · Published · 2021-01 · Application PCT/KR2021/000442
Rejected · 2020-12 · Application 1020200168874
Registered · 2020-12 · Application 1020200167816
JP · Published · 2020-03 · Application 32064958
Withdrawn · 2020-03 · Application 1020200038031
Expired · 2020-01 · Application 1020200008010
Registered · 2019-06 · Application 1020190077096
Rejected · 2019-06 · Application 1020190077095
CN · Published · 2019-01 · Application 201980020941.2
US · Published · 2019-01 · Application 16963046
EP · Registered · 2019-01 · Application 19741656.3
PCT · Published · 2019-01 · Application PCT/KR2019/000797
Registered · 2019-01 · Application 1020190007185
Withdrawn · 2018-12 · Application 1020180169075
US · Registered · 2018-12 · Application 16217962
CN · Published · 2018-06 · Application 201880055974.6
CN · Published · 2018-06 · Application 201880055969.5
US · Registered · 2018-06 · Application 16627528
US · Registered · 2018-06 · Application 16627541
EP · Published · 2018-06 · Application 26174992.3
EP · Registered · 2018-06 · Application 18823401.7
EP · Published · 2018-06 · Application 18824811.6
EP · Published · 2018-06 · Application 26163454.7
PCT · Published · 2018-06 · Application PCT/KR2018/007437
PCT · Published · 2018-06 · Application PCT/KR2018/007438
Rejected · 2018-06 · Application 1020180075978
Rejected · 2018-06 · Application 1020180075947
PCT · Published · 2018-06 · Application PCT/KR2018/006881
CN · Published · 2017-10 · Application 201780081884.X
US · Published · 2017-10 · Application 16346170
EP · Registered · 2017-10 · Application 17863851.6
PCT · Published · 2017-10 · Application PCT/KR2017/012136
JP · Registered · 2017-10 · Application 31523609
Registered · 2017-10 · Application 1020217026063
Rejected · 2017-10 · Application 1020197011633
CN · Published · 2017-07 · Application 201780058387.8
US · Registered · 2017-07 · Application 16319067
EP · Registered · 2017-07 · Application 17831389.6
PCT · Published · 2017-07 · Application PCT/KR2017/007896
JP · Registered · 2017-07 · Application 31502664
Registered · 2017-07 · Application 1020207035083
Registered · 2017-07 · Application 1020197005052
Registered · 2017-06 · Application 1020170077657
Registered · 2016-11 · Application 1020160159659
CN · Published · 2016-09 · Application 202110999106.7
CN · Published · 2016-09 · Application 201680053704.2
US · Registered · 2016-09 · Application 15754849
EP · Registered · 2016-09 · Application 16848886.4
PCT · Published · 2016-09 · Application PCT/KR2016/010480
JP · Registered · 2016-09 · Application 30515089
Registered · 2016-09 · Application 1020187005223
CN · Published · 2016-05 · Application 201680033531.8
US · Registered · 2016-05 · Application 15575470
EP · Registered · 2016-05 · Application 16803687.9
PCT · Published · 2016-05 · Application PCT/KR2016/005647
JP · Registered · 2016-05 · Application 30514761
CN · Published · 2016-02 · Application 201680008586.3
US · Registered · 2016-02 · Application 15547566
EP · Registered · 2016-02 · Application 16746880.0
PCT · Published · 2016-02 · Application PCT/KR2016/001310
JP · Registered · 2016-02 · Application 29538300
Registered · 2016-02 · Application 1020177020973
CN · Published · 2015-11 · Application 201580061479.2
US · Published · 2015-11 · Application 15525981
EP · Published · 2015-11 · Application 15859034.9
PCT · Published · 2015-11 · Application PCT/KR2015/012194
Withdrawn · 2015-09 · Application 1020150133349
Withdrawn · 2015-05 · Application 1020150076197
PCT · Published · 2015-05 · Application PCT/KR2015/004678
Withdrawn · 2015-05 · Application 1020177014904
PCT · Published · 2015-02 · Application PCT/KR2015/001566
Withdrawn · 2014-11 · Application 1020140159124
Rejected · 2014-10 · Application 1020140133407
PCT · Published · 2014-04 · Application PCT/KR2014/003024
TW · Published · 2013-11 · Application 102143795
PCT · Published · 2013-11 · Application PCT/KR2013/010899
Withdrawn · 2013-11 · Application 1020130142874
Expired · 2013-10 · Application 1020130121407
Withdrawn · 2013-02 · Application 1020130016818
Withdrawn · 2013-02 · Application 1020130016819
Withdrawn · 2012-12 · Application 1020120156051
PCT · Published · 2012-12 · Application PCT/KR2012/010690
Withdrawn · 2012-12 · Application 1020120141469
Withdrawn · 2012-11 · Application 1020120132614
Withdrawn · 2012-11 · Application 1020120132617
Withdrawn · 2012-11 · Application 1020120132615
Withdrawn · 2012-11 · Application 1020120131724
Withdrawn · 2012-11 · Application 1020120131789
Withdrawn · 2012-05 · Application 1020120055379
Withdrawn · 2012-02 · Application 1020120015235
Withdrawn · 2012-02 · Application 1020120015222
Rejected · 2012-01 · Application 1020120008215
Withdrawn · 2011-12 · Application 1020110148003
Withdrawn · 2011-12 · Application 1020110148017
Withdrawn · 2011-12 · Application 1020110148005
Withdrawn · 2011-12 · Application 1020110147964
Withdrawn · 2011-12 · Application 1020110146178
Withdrawn · 2011-12 · Application 1020110146169
Rejected · 2011-11 · Application 1020110117410
Rejected · 2011-07 · Application 1020110073057
Rejected · 2011-06 · Application 1020110055842
Withdrawn · 2010-12 · Application 1020100139794
Rejected · 2010-12 · Application 1020100135431
Rejected · 2010-11 · Application 1020100120032
PCT · Published · 2010-05 · Application PCT/KR2010/003057
Withdrawn · 2010-05 · Application 1020117024403
PCT · Published · 2010-03 · Application PCT/KR2010/001995
Withdrawn · 2010-03 · Application 1020117023157
Rejected · 2009-12 · Application 1020090135839
Withdrawn · 2009-07 · Application 1020090069144
Withdrawn · 2008-12 · Application 1020080137745
Withdrawn · 2008-12 · Application 1020080137817
Withdrawn · 2008-12 · Application 1020080137714
Withdrawn · 2008-12 · Application 1020080137720
Withdrawn · 2008-12 · Application 1020080137816
Withdrawn · 2008-11 · Application 1020080116272
Withdrawn · 2008-11 · Application 1020080116271
Withdrawn · 2008-10 · Application 1020080103599
Withdrawn · 2006-09 · Application 1020060085197
Withdrawn · 2006-02 · Application 1020060016141
Withdrawn · 2006-01 · Application 1020060008165
Withdrawn · 2005-12 · Application 1020050134144
Withdrawn · 2005-12 · Application 1020050133153
Withdrawn · 2005-12 · Application 1020050117368
Withdrawn · 2005-12 · Application 1020050117369
Withdrawn · 2005-10 · Application 1020050103402
Expired · 2005-08 · Application 1020050077779
Withdrawn · 2005-08 · Application 1020050072717
Expired · 2005-08 · Application 1020050071416
Withdrawn · 2005-06 · Application 1020050048778
Withdrawn · 2005-06 · Application 1020050047146
Withdrawn · 2005-03 · Application 1020050018588
Withdrawn · 2005-01 · Application 1020050007868
Withdrawn · 2005-01 · Application 1020050005329
Expired · 2005-01 · Application 1020050001557
Rejected · 2004-12 · Application 1020040117396
Withdrawn · 2004-12 · Application 1020040112657
Expired · 2004-12 · Application 1020040112656
Withdrawn · 2004-12 · Application 1020040111634
Expired · 2004-12 · Application 1020040106883
Rejected · 2003-12 · Application 1020030088879
EP · Registered · 2003-08 · Application 03788171.1
Rejected · 2003-06 · Application 1020030042339
Rejected · 2003-06 · Application 1020030040972
Expired · 2003-04 · Application 1020030027394
Rejected · 2002-12 · Application 1020020076574
Expired · 2002-11 · Application 1020020071140
Expired · 2002-11 · Application 1020020071209
Expired · 2002-08 · Application 1020020048916
Expired · 2001-12 · Application 1020010077028
Expired · 2001-12 · Application 1020010077029
Expired · 2000-08 · Application 1020000046179
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot42
- GoogleGoogleOther3
- AnthropicClaudeBot2
- MicrosoftBingbot1
- PerplexityPerplexityBot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KOLON LIFE SCIENCE Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition